Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor

Cutis

Volumn 66, Issue 1, 2000, Pages 29-32

  Smith, Kathleen J ^a   Yeager, Josef ^a   Skelton, Henry ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; BIOPSY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG ERUPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATHOLOGY; SKIN;

ADULT; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; SAQUINAVIR; SKIN;

EID: 0034231017     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Wlodawer A, Miller M, Jaskolski M, et al: Conserved folding in retro-viral proteases crystal structure of a synthetic HIV-1 proteinase. Science 245: 616-621, 1989.
2. West ML, Fairlie DP: Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol Sci 16: 67-75, 1995.
3. Hammer SM: Advances in antiretroviral therapy and viral load monitoring. AIDS 10: S1-S11, 1996.
4. Boucher C: Rational approaches to resistance: using saquinavir. AIDS 10: S15-S19, 1996.
5. Moyle G, Gazzard B: Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 51: 701-712, 1996.
6. Eagling VA, Back DJ, Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 44: 190-194, 1997.
7. Chiba M, Hensleigh M, Nishime DJA, et al: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24: 307-314, 1996.
8. Singer MI, Shapiro LE, Shear NH: Cytochrome P-450 3A: interactions with dermatologic therapies. J Am Acad Dermatol 37: 765-771, 1997.
9. Smith KJ, Skelton HG, Yeager J, et al: Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. Clin Exp Dermatol 22: 118-123, 1997.
10. Studt T: Maturing combinatorial chemistry creates new technology base. Res Develop 39: 32-34, 1997.
11. Douglas R, Spelman D, Czarny D, et al: Successful desensitization of two patients who previously developed Stevens Johnson syndrome while receiving trimethoprim-sulfamethoxazole. Clin Infect Dis 6: 1480, 1997.
12. Ribeiro LM, Pastorino AC, Grumach AS, et al: Drug hypersensitivity in AIDS patients. Report of a case. Rev Hosp Clin Fac Med Sao Paulo 52: 23-27, 1997.
13. Kalanadhabhatta V, Muppidi D, Sahni H, et al: Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome. Ann Allergy Asthma Immunol 77: 394-400, 1996.
14. Caumes E, Guermonprez G, Leomte C, et al: Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 133: 465-469, 1997.
15. Carr A: Role of densensitization for drug hypersensitivity in patients with HIV infection. Drug Safety 17: 119-126, 1997.
16. Shiohara T, Nickoloff BJ, Sagawa Y, et al: Fixed drug eruption. Expression of epidermal keratinocyte intercellular adhesion molecule-1 (ICAM-1). Arch Dermatol 125: 1371-1376, 1989.